Деэскалация системной терапии раннего и местно-распространенного тройного негативного рака молочной железы

Неоадъювантная химиотерапия (НАХТ) раннего и местно-распространенного тройного негативного рака молочной железы (ТНРМЖ) является обязательным звеном в составе радикального лечения. Достижение полного патоморфологического регресса (пПР) определяет прогноз заболевания, позволяет провести органосохраняющее лечение, а также снижает риск рецидива и улучшает общую выживаемость. В последнее время наблюдается увеличение количества исследований, направленных на интенсификацию НАХТ, что объясняется известной агрессивностью данного подтипа рака молочной железы. Однако, увеличение частоты и тяжести нежелательных явлений, часто нивелирующих улучшение эффекта лечения, привели к появлению исследований, направленных на снижение химиотерапевтической нагрузки НАХТ ТНРМЖ без потери его эффективности. Изучаемые схемы химиотерапии могут стать новыми стандартами неоадъювантного этапа комплексного лечения резектабельных форм ТНРМЖ. В этом обзоре рассмотрен текущий стандарт системного лечения раннего и местно-распространенного ТНРМЖ, а также возможные варианты деэскалации лекарственной терапии.

1. Cancer Today [Electronic resource]. URL: https://gco.iarc.who.int/today/en/dataviz/pie?mode=cancer&group_populations=1&types=1&populations=900&-sexes=2

2. S SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2024 Apr 17. [updated: 2024 Nov 5; cited 2025 Jan 29]. Available from: https://seer.cancer.gov/statistics-network/explorer/. Data source(s): SEER Incidence Data, November 2023 Submission (1975–2021), SEER 22 registries [Electronic resource]. URL: https://seer.cancer.gov/statistics-network/explorer/application.html?site=623&-data_type=4&graph_type=5&compareBy=stage&chk_stage_104=104&chk_stage_105=105&series=9&hdn_sex=3&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0.

3. Rebecca Dent; Maureen Trudeau; Kathleen I. Pritchard et al. Triple-negative breast cancer: clinical features and patterns of recurrence // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007. Vol. 13, № 15 Pt 1. P. 4429–4434. DOI: 10.1158/1078–0432.CCR-06–3045. URL: https://aacrjournals.org/clincancerres/article/13/15/4429/194334/Triple-Negative-Breast-Cancer-Clinical-Features

4. Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer | Journal of Clinical Oncology 2008. Vol. 26, № 8. DOI: 10.1200/JCO.2007.14.4147 [Electronic resource]. URL: https://ascopubs.org/doi/10.1200/JCO.2007.14.4147?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

5. Norman Wolmark, Jiping Wang, Eleftherios Mamounas. et al. Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18 // JNCI Monogr. 2001. Vol. 2001, № 30. P. 96–102. DOI: 10.1093/oxfordjournals.jncimonographs.a003469. URL: https://academic.oup.com/jncimono/article/2001/30/96/936263?login=true.

6. C. E. Geyer, W. M. Sikov, J. Huober. et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial // Ann. Oncol. Elsevier, 2022. Vol. 33, № 4. P. 384–394. DOI: 10.1016/j.annonc.2022.01.009. URL: https://www.sciencedirect.com/science/article/pii/S0923753422000187?via%3Dihub.

7. Prof Sibylle Loibl MD, Joyce O’Shaughnessy MD, Prof Michael Untch MD. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighT-Ness): a randomised, phase 3 trial // Lancet Oncol. Elsevier, 2018. Vol. 19, № 4. P. 497–509. DOI: 10.1016/S1470–2045(18)30111-6. URL: https://www.sciencedirect.com/science/article/abs/pii/S1470204518301116?via%3Dihub.

8. Hermela Shimelis, Holly LaDuca, Chunling Hu. et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing | JNCI: Journal of the National Cancer Institute | Oxford Academic, 2018. Vol. 110, № 8. P. 855–862. DOI: 10.1093/jnci/djy106. URL: https://academic.oup.com/jnci/article/110/8/855/5062996?login=false.

9. Amanda B Spurdle, Fergus J Couch, Michael T Parsons. et al. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 16, 3419 (2014). DOI: 10.1186/s13058–014–0474-y. URL: https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-014-0474-y.

10. T. Byrski, T. Huzarski, R. Dent. et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients // Breast Cancer Res. Treat. 2009. Vol. 115, № 2. P. 359–363. DOI: 10.1007/s10549-008-0128-9. URL: https://link.springer.com/article/10.1007/s10549-008-0128-9.

11. Daniel P. Silver, Andrea L. Richardson, Aron C. Eklund. et al. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer // J. Clin. Oncol. Wolters Kluwer, 2010. Vol. 28, № 7. P. 1145–1153. DOI: 10.1200/JCO.2009.22.4725. URL: https://ascopubs.org/doi/10.1200/JCO.2009.22.4725?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

12. William M. Sikov, Don S. Dizon, Rochelle Strenger. et al. Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study | Journal of Clinical Oncology, 2009. Vol. 27, № 28. URL: https://ascopubs.org/doi/10.1200/JCO.2008.21.4163?url_ver=Z39.88-2003&r-fr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

13. William M. Sikov, Donald A. Berry, Charles M. Perou. et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015. Vol. 33, № 1. P. 13–21. DOI: 10.1200/JCO.2014.57.0572. URL: https://ascopubs.org/doi/10.1200/JCO.2014.57.0572?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&r-fr_dat=cr_pub%20%200pubmed.

14. Prof Gunter von Minckwitz MD, Prof Andreas Schneeweiss MD, Prof Sibylle Loibl MD. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial – The Lancet Oncology, 2014. Vol. 15, № 7. P. 747–756. DOI: 10.1016/S1470–2045(14)70160-3. URL: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70160-3/abstract.

15. Masashi Ando, Hideko Yamauchi, Kenjiro Aogi. et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment, 2014. Vol. 145. P. 401–409. DOI: 10.1007/s10549-014-2947-1 URL: https://link.springer.com/article/10.1007/s10549-014-2947-1.

16. Eric Hahnen, Ph D. Bianca Lederer, Ph D. Jan Hauke, Ph D. et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial // JAMA Oncol. 2017. Vol. 3, № 10. P. 1378–1385. DOI: 10.1001/jamaoncol.2017.1007. URL: https://jamanetwork.com/journals/jamaoncology/fullarticle/2643514.

17. F. Poggio. M. Bruzzone. M. Ceppi. et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Annals of Oncology, 2018. Vol. 29, № 7. P. 1497–1508. DOI: 10.1093/annonc/mdy127. URL: https://www.annalsofoncology.org/article/S0923-7534(19)32098-8/fulltext#secst0080.

18. F. Poggio. M. Tagliamento. M. Ceppi. et al. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate // Ann. Oncol. Elsevier, 2022. Vol. 33, № 3. P. 347–349. DOI: 10.1016/j.annonc.2021.11.016. URL: https://www.sciencedirect.com/science/article/pii/S0923753421048316?via%3Dihub.

19. Gupta S. Nair NS. Hawaldar RW. et al. Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6–10, 2022; San Antonio, TX. Abstract GS 5–01.

20. P. Schmid. J. Cortés. R. A. Dent. et al. LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study // Ann. Oncol. 2023. Vol. 34. P. S 1257. DOI: 10.1016/j.annonc.2023.10.008. URL: https://www.sciencedirect.com/science/article/pii/S0923753423041522?via%3Dihub.

21. Loibl S. et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up // Ann. Oncol. Elsevier, 2024. Vol. 35, № 2. P. 159–182.

22. NSABP Foundation Inc. A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo: Clinical trial registration NCT03281954. clinicaltrials.gov, 2024. SABCS 2024.

23. Charles E. Geyer, Sibylle Loibl, Priya Rastogi. et al. NSABP B-59/GBG 96-Gepar-Douze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. // J. Clin. Oncol. American Society of Clinical Oncology, 2019. Vol. 37, № 15. DOI: 10.1200/JCO.2019.37.15_suppl.TPS605. URL: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.TPS605.

24. Swain S. M., Whaley F. S., Ewer M. S. Congestive heart failure in patients treated with doxorubicin, 2003. Vol. 97, № 11. DOI: 10.1002/cncr.11407. URL: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.11407.

25. Geoffrey Bostany, BA, Yanjun Chen, MS, Liton Francisco, BA. et al. Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors. Journal of Clinical Oncology, 2025. Vol. 43, № 1. P. 32–45. DOI: 10.1200/JCO.23.01779. URL: https://ascopubs.org/doi/10.1200/JCO.23.01779.

26. Stephen Jones Steve. Frankie Ann Holmes. Joyce O’Shaughnessy. et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Journal of Clinical Oncology, 2009. Vol. 27, № 8. P. 1177–1183. DOI: 10.1200/JCO.2008.18.4028. URL: https://ascopubs.org/doi/10.1200/JCO.2008.18.4028?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

27. Ulrike Nitz, MD. Oleg Gluz, MD. Michael Clemens, MD. et al. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer // J. Clin. Oncol. Wolters Kluwer, 2019. Vol. 37, № 10. P. 799–808. DOI: 10.1200/JCO.18.00028. URL: https://ascopubs.org/doi/10.1200/JCO.18.00028?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&r-fr_dat=cr_pub%20%200pubmed.

28. Sofia Re Mason. Melina L Willson. Sam J Egger. et al. Platinum chemotherapy for early triple-negative breast cancer // Breast Edinb. Scotl. 2024. Vol. 75. P. 103712. DOI: 10.1016/j.breast.2024.103712. URL: https://www.sciencedirect.com/science/article/pii/S0960977624000432?via%3Dihub.

29. Pin Zhang1. Yi Yin. Hongnan Mo. et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial // Oncotarget. 2016. Vol. 7, № 37. P. 60647–60656. DOI: 10.18632/oncotarget.10607. URL: https://www.oncotarget.com/article/10607/text/.

30. Liulu Zhang, Zhi-Yong Wu, Jie Li. et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial // Int. J. Cancer. 2022. Vol. 150, № 4. P. 654–662. DOI: 10.1002/ijc.33830. URL: https://onlinelibrary.wiley.com/doi/10.1002/ijc.33830.

31. Priyanka Sharma; Bruce F. Kimler. Anne O’Dea. et al. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP) // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2021. Vol. 27, № 4. P. 975–982. DOI: 10.1158/1078–0432.CCR-20–3646. URL: https://aacrjournals.org/clincancerres/article/27/4/975/125183/Randomized-Phase-II-Trial-of-Anthracycline-free.

32. О. О. Гордеева. И. В. Колядина. Л. Г. Жукова et al. Эффективность и безопасность неоадъювантной химиотерапии в режиме PlaTax у больных трижды негативным раком молочной железы II–III стадий. Опухоли женской репродуктивной системы, 2020. Vol. 16, № 2. DOI: 10.17650/1994-4098-2020-16-2-25-37. URL: https://cyberleninka.ru/article/n/effektivnost-i-bezopasnost-neoadyuvantnoy-himioterapii-v-rezhime-platax-u-bolnyh-trizhdy-negativnym-rakom-molochnoy-zhelezy-ii-iii/viewer

33. Andrew Tutt. Holly Tovey. Maggie Chon U. Cheang. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine, 2018. Vol. 24. P. 628–637. DOI: 10.1038/s41591-018-0009-7. URL: https://www.nature.com/articles/s41591-018-0009-7?error=cookies_not_supported&code=012e3d9b-de01-4f5d-ab67-60343f10d4f8.

34. Priyanka Sharma, MD 1. Shane R. Stecklein, MD, Ph D. Rachel Yoder, MS. et al. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial // JAMA Oncol. 2024. Vol. 10, № 2. P. 227–235. DOI: 10.1001/jamaoncol.2023.5033. URL: https://jamanetwork.com/journals/jamaoncology/fullarticle/2812294